BID or QD regiments do not make much difference for either patients or doctors. It is just matter of convinience. These drugs will not be taken on perminent bases similar HIV drugs.
There is absolutely no stat differences between 96% and 99% based on 100 pts sampling.
Based on the ION-2 data, GILD’s GT1 regimen will include ribavirin for treatment-experienced patients, which means the regimen will effectively be BID, not qD. For treatment-naïve patients (possibly excluding cirrhotics), GILD will have a bona fide qD regimen.
Market Data 
Markets 
AI
